clinical trial · NCT07083193
A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis
Accro Bioscience (Suzhou) Limited·phase2·recruiting·n = 24
Ulcerative ColitisAC-101
brief summary
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of AC-101 tablets in participants with moderate-to-severe ulcerative colitis. The total study duration is up to 17 weeks, including 4-week screening, 12-week treatment period, and 1-week safety follow-up. The study will enroll approximately 24 participants with moderate to severe active ulcerative colitis.
started
Jan 20, 2025
primary completion
Sep 30, 2026
completion
Apr 30, 2027
last updated
Jul 24, 2025
official title
A Phase 1b, Multicenter, Open-label, Randomized Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol